Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
683 Phase I first-in-human study on the feasibility, safety, and antitumor activity of CD4-redirected chimeric antigen receptor (CAR) T-cell therapy in patients with CD4+ T-cell malignancies (TCM)
Compose a Response to This Article
Other responses
No responses have been published for this article.
